Claims for Patent: 9,359,617

Summary for Patent: 9,359,617

Title:	Mammalian expression vector
Abstract:	The present invention describes new mammalian expression vectors comprising a novel combination of regulatory elements and one or more selection marker gene(s). The vector allows for incorporation of at least one, preferably two or more genes of interest, its/their subsequent expression, and for selection of transfected cells using, e.g., G418 and/or MTX. The pDGP.DELTA.GOI vector as an example for a mammalian expression vector according to the present invention exhibits a 9555 bp sequence, one strand of which is represented by SEQ ID NO:2.
Inventor(s):	Francky; Andrej (Menges, SI), Gaser; Dominik (Menges, SI)
Assignee:	LEK PHARMACEUTICALS D.D. (Ljubljana, SI)
Application Number:	13/141,005
Patent Claims:	1. A mammalian expression vector comprising the following regulatory elements: (a) a simian virus 40 enhancer and early promoter region; (b) human Hbb intronII; and (c) at least one gene encoding a polypeptide of interest, wherein the human Hbb intron II is located between (i) the simian 40 virus enhancer and early promoter region and (ii) the at least one gene encoding a polypeptide of interest. 2. The vector of claim 1, wherein the human Hbb intron II comprises the sequence of SEQ ID NO:1. 3. The vector of claim 1, wherein the vector further comprises at least one gene encoding a eukaryotic and/or prokaryotic selection marker. 4. The vector of claim 3, wherein the order of the regulatory elements, the at least one gene encoding the polypeptide of interest and the gene encoding a eukaryotic and/or prokaryotic selection marker is as follows: (i) 5'-SV40 enhancer/early promoter region, Hbb intron II, gene encoding the light chain of an immunoglobulin, SV40 polyadenylation signal sequence; (ii) SV40 enhancer/early promoter region, Hbb intron II, gene encoding the heavy chain of an immunoglobulin, SV40 polyadenylation signal sequence; (iii) SV40 enhancer/early promoter region, Tn5 neomycin phosphotransferase gene, a synthetic polyadenylation signal sequence; (iv) SV40 early promoter, dihydrofolate reductase gene, SV40 polyadenylation signal sequence-3'. 5. The vector of claim 3, wherein the at least one eukaryotic selection marker gene is the neomycin phosphotransferase gene from Tn5 and/or the dihydrofolate reductase gene. 6. The vector of claim 1, wherein the vector is circular and/or the at least one gene encoding the polypeptide of interest is under the control of (a) and (b). 7. The vector of claim 6, wherein the at least one gene encoding the polypeptide of interest encodes an immunoglobulin light chain and/or an immunoglobulin heavy chain. 8. The vector of claim 1, wherein the vector is the pDGP.DELTA.GOI vector exhibiting a 9555 bp sequence, one strand of which being represented by SEQ ID NO:2. 9. The vector of claim 8, wherein the vector is circular. 10. A vector system comprising at least two of the expression vector of claim 1. 11. The vector system of claim 10, wherein a first gene encoding a first polypeptide of interest located on a first vector encodes the light chain of an immunoglobulin, and a second gene encoding a second polypeptide of interest located on a second vector encodes the heavy chain of an immunoglobulin. 12. The vector system of claim 10, wherein a first vector comprises the at least one gene encoding the polypeptide of interest, and wherein a second vector comprises at least one gene encoding a selection marker conferring resistance to a transfected cell. 13. The vector system of claim 10, wherein a first vector is the pDGP-A.DELTA.GOI vector exhibiting a 3830 bp sequence, one strand of which being represented by SEQ ID NO:3. 14. An isolated mammalian cell comprising the expression vector of claim 1. 15. The cell of claim 14, wherein the cell is selected from the group consisting of: a COP cell, an L cell, a C127 cell, an Sp2/0 cell, an NS-0 cell, an NIH3T3 cell, a PC12 cell, a PC12h cell, a BHK cell, a CHO cell, a COS1 cell, a COS3 cell, a COST cell, a CV1 cell, a Vero cell, a HeLa cell, an HEK-293 cell, a PER C6 cell, a cell derived from diploid fibroblasts, myeloma cells, and HepG2. 16. An ex vivo-method for producing a cell comprising an expression vector comprising contacting a mammalian cell with the mammalian expression vector of claim 1. 17. A method for producing at least one polypeptide of interest comprising culturing a cell comprising the mammalian expression vector of claim 1 in a cell culture medium under conditions allowing expression of said at least one polypeptide of interest. 18. The method of claim 17, wherein said at least one polypeptide of interest is/are secreted into the cell culture medium and said method further comprises the step of isolating from the cell culture medium said at least one polypeptide of interest. 19. An isolated mammalian cell comprising the vector system of claim 10. 20. An ex vivo-method for producing a cell comprising a vector system comprising contacting a mammalian cell with the vector system of claim 10.

Details for Patent 9,359,617

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2028-12-22
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2028-12-22
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2028-12-22